Drug Patents owned by Glaxosmithkline
1. List of Advil Allergy Sinus drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7863287 | GLAXOSMITHKLINE | Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines |
Feb, 2027
(4 years from now) | |
Market Authorisation Date: 19 December, 2002
Treatment: NA
Dosage: TABLET;ORAL
2. List of Advil Pm drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8883849 | GLAXOSMITHKLINE | Treatment of sleep disturbances |
Jan, 2022
(1 year, 19 days ago) | |
| US9155718 | GLAXOSMITHKLINE | Treatment of sleep disturbances |
Jan, 2022
(1 year, 19 days ago) | |
Drugs and Companies using DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN ingredient
Market Authorisation Date: 21 December, 2005
Treatment: A method of treating a patient suffering from a pain associated sleep disturbance comprising administering a liquid composition formulated inside a soft gel capsule, as claimed, to the patient
Dosage: CAPSULE;ORAL
3. List of Advil Pm drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8263647 | GLAXOSMITHKLINE | Treatment of sleep disturbances |
May, 2022
(8 months ago) | |
Drugs and Companies using DIPHENHYDRAMINE CITRATE; IBUPROFEN ingredient
Market Authorisation Date: 21 December, 2005
Treatment: NA
Dosage: TABLET;ORAL
4. List of Anoro Ellipta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE44874 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(a month from now) | |
| US7498440 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(2 years from now) | |
| US7439393 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(2 years from now) | |
| US7488827 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Dec, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7776895 | GLAXOSMITHKLINE | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
Sep, 2022
(4 months ago) | |
| US8309572 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(2 years from now) | |
| US8183257 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Jul, 2025
(2 years from now) | |
| US8511304 | GLAXOSMITHKLINE | Medicament dispenser |
Jun, 2027
(4 years from now) | |
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(4 years from now) | |
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(4 years from now) | |
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(5 years from now) | |
| US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(7 years from now) | |
| US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(7 years from now) | |
| US9750726 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(7 years from now) | |
| US11090294 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jun 9, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient
Market Authorisation Date: 18 December, 2013
Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.; Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: POWDER;INHALATION
5. List of Arnuity Ellipta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(4 years from now) | |
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(4 years from now) | |
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(5 years from now) | |
| US8201556 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2029
(6 years from now) | |
| US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(7 years from now) | |
| US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(7 years from now) | |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 20 August, 2014
Treatment: NA
Dosage: POWDER;INHALATION
6. List of Children's Advil drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10238640 | GLAXOSMITHKLINE | Pharmaceutical suspension composition |
May, 2024
(1 year, 3 months from now) | |
Drugs and Companies using IBUPROFEN ingredient
Market Authorisation Date: 27 June, 1996
Treatment: NA
Dosage: SUSPENSION;ORAL
7. List of Children's Advil Allergy Sinus drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10238640 | GLAXOSMITHKLINE | Pharmaceutical suspension composition |
May, 2024
(1 year, 3 months from now) | |
Market Authorisation Date: 24 February, 2004
Treatment: NA
Dosage: SUSPENSION;ORAL
8. List of Nicorette drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8323683 | GLAXOSMITHKLINE | Flavoring of drug-containing chewing gums |
Apr, 2028
(5 years from now) | |
| US8940772 | GLAXOSMITHKLINE | Nicotine lozenge composition |
Apr, 2029
(6 years from now) | |
| US8501164 | GLAXOSMITHKLINE | Nicotine lozenge compositions |
Jun, 2029
(6 years from now) | |
Drugs and Companies using NICOTINE POLACRILEX ingredient
Market Authorisation Date: 09 February, 1996
Treatment: NA
Dosage: GUM, CHEWING;BUCCAL
9. List of Trelegy Ellipta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE44874 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(a month from now) | |
| US7498440 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(2 years from now) | |
| US7439393 | GLAXOSMITHKLINE | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(2 years from now) | |
| US7488827 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Dec, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7776895 | GLAXOSMITHKLINE | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
Sep, 2022
(4 months ago) | |
| US8309572 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Apr, 2025
(2 years from now) | |
| US8183257 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Jul, 2025
(2 years from now) | |
| US8511304 | GLAXOSMITHKLINE | Medicament dispenser |
Jun, 2027
(4 years from now) | |
| US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(4 years from now) | |
| US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(4 years from now) | |
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(5 years from now) | |
| US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(7 years from now) | |
| US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(7 years from now) | |
| US11090294 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(7 years from now) | |
| US9750726 | GLAXOSMITHKLINE | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist |
Nov, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Strength (NS) | Sep 9, 2023 |
| New Indication (I) | Sep 9, 2023 |
Market Authorisation Date: 18 September, 2017
Treatment: Method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via topical application; Method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via inhalation; Method of dispensing a combination medicament product from claimed delivery device, for example for the treatment of asthma or copd; Maintenance treatment of chronic obstructive pulmonary disease (copd) comprising the once per day administration of trelegy ellipta, 100 mcg fluticasone furoate/62.5 mcg umeclidinium/25 mcg vilanterol; Indicated for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema; And asthma; Maintenance treatment of asthma in patients 18 yrs and older, or chronic obstructive pulmonary disease (copd) including chronic bronchitis and/or emphysema
Dosage: POWDER;INHALATION
10. List of Ventolin Hfa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7832351 | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Jun, 2023
(4 months from now) | |
|
US7832351
(Pediatric) | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Dec, 2023
(10 months from now) | |
| US7500444 | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Feb, 2026
(3 years from now) | |
|
US7500444
(Pediatric) | GLAXOSMITHKLINE | Actuation indicator for a dispensing device |
Aug, 2026
(3 years from now) | |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 19 April, 2001
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
11. List of Zejula drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8436185 | GLAXOSMITHKLINE | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide |
Apr, 2029
(6 years from now) | |
| US8071623 | GLAXOSMITHKLINE | Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors |
Mar, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071579 | GLAXOSMITHKLINE | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(4 years from now) | |
| US8143241 | GLAXOSMITHKLINE | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(4 years from now) | |
| US8859562 | GLAXOSMITHKLINE | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(8 years from now) | |
| US11091459 | GLAXOSMITHKLINE | Niraparib compositions |
Mar, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 29, 2027 |
| New Chemical Entity Exclusivity (NCE) | Mar 27, 2022 |
| New Indication (I) | Apr 29, 2023 |
Drugs and Companies using NIRAPARIB TOSYLATE ingredient
NCE-1 date: March, 2021
Market Authorisation Date: 27 March, 2017
Treatment: A method of treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer associated with homologous recombination deficiency (hrd) positive status
Dosage: CAPSULE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic